Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib OLE in Primary Immunodeficiency Disorders
NCT06990529Phase 2Active, not recruiting
- Sponsor
- Pharming Group
- Start
- Apr 2025
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of leniolisib in primary immunodeficiency disorder (PID), sponsored by Pharming Group. Started Apr 2025; status: active, not recruiting.
02
Drugs
leniolisib
03
Conditions
primary immunodeficiency disorder (PID)
Beyond the preview
Go deeper on NCT06990529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990529.